Language:

Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2

Revue médicale suisse, 2022-08, Vol.18 (792), p.1539-1544 [Peer Reviewed Journal]

ISSN: 1660-9379 ;DOI: 10.53738/REVMED.2022.18.792.1539 ;PMID: 36004653

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2
Author: Scheen, André J. ; Radermecker, Régis P. ; Paquot, Nicolas
Subjects: Blood Glucose ; Diabetes Mellitus, Type 2/drug therapy/metabolism ; Endocrinologie, métabolisme & nutrition ; Endocrinology, metabolism & nutrition ; Gastric Inhibitory Polypeptide ; Glucagon-Like Peptide 1 ; Glucagon-Like Peptide-1 Receptor ; Glucagon-Like Peptide-1 Receptor/agonists ; Human health sciences ; Humans ; Hypoglycemic Agents ; Hypoglycemic Agents/therapeutic use ; OYN3CCI6QE (tirzepatide) ; Pharmacie, pharmacologie & toxicologie ; Pharmacy, pharmacology & toxicology ; Sciences de la santé humaine
Is Part Of: Revue médicale suisse, 2022-08, Vol.18 (792), p.1539-1544
Description: Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as once-weekly injection for the treatment of type 2 diabetes. Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, basal insulin and two GLP-1 analogues (dulaglutide and semaglutide) in the SURPASS program. Its cardiovascular protection (versus dulaglutide) is currently tested in SURPASS-CVOT. Finally, studies for the treatment of obesity and metabolic associated fatty liver disease are also ongoing. Gastrointestinal tolerance of tirzepatide appears comparable to that of GLP-1 analogues, except more diarrhoea.
Publisher: Medecine et Hygiène
Language: English;French
Identifier: ISSN: 1660-9379
DOI: 10.53738/REVMED.2022.18.792.1539
PMID: 36004653
Source: Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2

ISSN: 1660-9379 ;DOI: 10.53738/REVMED.2022.18.792.1539 ;PMID: 36004653

Searching Remote Databases, Please Wait